Coverart for item
The Resource Frontiers in Gynecological Endocrinology : Volume 4: Pediatric and Adolescent Gynecological Endocrinology

Frontiers in Gynecological Endocrinology : Volume 4: Pediatric and Adolescent Gynecological Endocrinology

Label
Frontiers in Gynecological Endocrinology : Volume 4: Pediatric and Adolescent Gynecological Endocrinology
Title
Frontiers in Gynecological Endocrinology
Title remainder
Volume 4: Pediatric and Adolescent Gynecological Endocrinology
Creator
Contributor
Subject
Language
eng
Member of
Cataloging source
MiAaPQ
Literary form
non fiction
Nature of contents
dictionaries
Series statement
ISGE Series
Frontiers in Gynecological Endocrinology : Volume 4: Pediatric and Adolescent Gynecological Endocrinology
Label
Frontiers in Gynecological Endocrinology : Volume 4: Pediatric and Adolescent Gynecological Endocrinology
Link
http://libproxy.rpi.edu/login?url=https://ebookcentral.proquest.com/lib/rpi/detail.action?docID=4806839
Publication
Copyright
Related Contributor
Related Location
Related Agents
Related Authorities
Related Subjects
Related Items
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Preface -- Contents -- 1: Dimorphism of Human Brain: The Basis of the Gender Differences -- References -- 2: Management of Disorders of Sex Development -- 2.1 Diagnosis of the Disorders of Sex Differentiation (DSD) -- 2.1.1 Clinical Diagnosis of DSD -- 2.1.2 Genetic Investigations -- 2.1.3 Hormonal Investigations -- 2.1.4 Imaging -- 2.2 Causes of DSD -- 2.2.1 46,XX DSD -- 2.2.1.1 Fetal Hyperandrogenism -- 2.2.1.2 Exogenous Hyperandrogenism -- 2.2.1.3 Abnormalities in Gonadal Determination -- 2.2.2 46,XY DSD -- 2.2.2.1 Gonadal Dysgenesis -- SRY Gene Abnormalities -- Abnormalities in Other Sex Determination Genes -- 2.2.2.2 Defects in Testosterone Production -- Defect in 3-Beta-Hydroxysteroid Dehydrogenase -- Defect of 17-Alpha-Hydroxylase -- Defect of 17-Beta-Hydroxysteroid Reductase -- P450-Oxydoreductase (POR) Deficit -- Leydig Cell Agenesis or Hypoplasia -- 2.2.2.3 Androgen-Resistance Disorders -- Androgen Insensitivity (AI) -- 5aR Deficiency -- MALD1 Gene Mutations -- 46,XY DSD and the Environment -- 2.2.3 Ovotesticular DSD -- 2.2.4 DSD Caused by Chromosomal Abnormalities -- 2.3 Elements for Gender Declaration -- References -- 3: Central Precocious Puberty: From Diagnosis to Treatment -- 3.1 Introduction -- 3.2 Etiologies and Mechanisms Underlying Premature Sexual Development -- 3.3 Consequences of Precocious Puberty -- 3.4 Evaluation of the Child with Premature Sexual Development -- 3.4.1 Clinical Diagnosis -- 3.4.2 Biological Diagnosis -- 3.4.3 Place of Imaging in the Evaluation of Precocious Puberty -- 3.4.4 The Normal Variants of Puberty -- 3.4.5 Psychosocial Aspects -- 3.5 Management of Central Precocious Puberty -- 3.5.1 GnRH Agonists -- 3.5.2 Management of Causal Lesions -- References -- 4: Management of Peripheral Precocious Puberty in Girls -- 4.1 Evaluation of the Pubertal Stage
  • 4.2 Clinical Expression of Peripheral Precocious Puberty -- 4.2.1 Peripheral Precocious Puberty Caused by Ovarian Autonomy -- 4.2.1.1 McCune-Albright Syndrome -- Precocious Puberty -- Café-au-lait Spots -- Fibrous Bone Dysplasia -- Other Endocrine Pathologies -- Molecular Bases of McCune-Albright Syndrome -- 4.2.1.2 Granulosa Cell Tumors -- 4.2.1.3 Ovarian Cysts -- 4.2.2 Feminizing Tumors of the Adrenal Gland -- 4.2.3 Precocious Pseudopuberty and Environmental Pollution -- References -- 5: Premature Pubarche -- 5.1 Definition -- 5.2 Adrenarche -- 5.3 Clinical Features -- 5.4 Evaluation of Girls with PP -- 5.5 Differential Diagnosis -- 5.5.1 Precocious Puberty -- 5.5.2 Non-classical Congenital Adrenal Hyperplasia (NC-CAH) -- 5.5.3 Virilizing Adrenal Tumors -- 5.5.4 Exogenous Androgen Exposure -- 5.6 Management -- References -- 6: Maturation of the Hypothalamic-{u00AD}Pituitary-{u00AD}Ovarian Axis and the Onset of Puberty -- 6.1 Introduction -- 6.2 Neuronal Control of Puberty: Essential Roles of GnRH and Kisspeptin (KP) Neurons -- 6.3 Roles of KP Partners in Pubertal Onset -- 6.4 Metabolic Control of Puberty -- 6.5 Novel Mechanism in the Control of Puberty -- References -- 7: From Primary Hypergonadotropic Amenorrhea to "POI": Aetiology and Therapy -- 7.1 POI Pathophysiology -- 7.2 POI Aetiology -- 7.2.1 Genetic Disorders -- 7.2.2 X Chromosome Numerical Defects -- 7.2.3 X Chromosome Structural Abnormalities and X-Autosome Translocations -- 7.2.4 Autosomal Rearrangements -- 7.2.5 Single Genes Responsible for Non-syndromic POF -- 7.2.6 Chromosomes with Autosomal Genes that Are Strong Candidates as a Cause of POF -- 7.2.7 Pleiotropic Single Gene Disorders in POF -- 7.2.8 Mitochondrial Genes Causing POF -- 7.2.9 Other Genetic Syndromes -- 7.2.10 Autoimmunologic Causes -- 7.2.11 Iatrogenic Causes -- 7.2.12 Infectious Causes
  • 7.2.13 Environmental Toxins -- 7.2.14 Other Causes of POF -- 7.3 Hormonal Replacement Therapy (HRT) in POI -- 7.3.1 Choice of Therapy -- 7.3.2 Therapeutic Targets -- 7.3.2.1 Estrogen Replacement Therapy for Puberty Induction in Gonadal Dysgenesis -- 7.3.3 Estrogens Used in HRT -- 7.3.4 Puberty Induction with Transdermal 17Ý-Estradiol -- 7.3.5 Puberty Induction with Percutaneous 17Ý-Estradiol in Hydroalcoholic Gel -- 7.3.6 Puberty Induction with Depot 17Ý-Estradiol Cypionate -- 7.3.7 Puberty Induction with Oral Estrogens -- 7.3.7.1 Puberty Induction with 17Ý-Estradiol (E2) -- 7.3.7.2 Puberty Induction with Ethinyl Estradiol (EE2) -- 7.3.7.3 Puberty Induction with Conjugated Equine Estrogens (CEE) -- 7.3.8 Progesterone and/or Progestin Addition -- 7.3.8.1 Micronized Progesterone for Oral Administration -- 7.3.8.2 Progestins -- 7.3.9 Special Considerations in Choosing Hormone Replacement Therapy -- 7.3.10 Effects of Hormone Replacement Therapy -- 7.3.10.1 Treatment to Improve Bone Mineral Density in Turner's Syndrome -- 7.4 Hormonal Therapy in POI with Post-menarche Onset -- 7.4.1 Bone Mineral Density in POI with Post-menarche Onset -- 7.4.2 Cognitive Function in POI -- 7.4.3 Psychological Consequences of POI -- 7.4.4 Androgen Deficiency in POI -- 7.4.5 Testosterone Replacement Therapy -- 7.4.6 DHEA Therapy -- References -- 8: Functional Hypothalamic Amenorrhea as Stress Induced Defensive System -- 8.1 Introduction -- 8.2 Functional Hypothalamic Amenorrhea (FHA) -- 8.3 Epidemiology and Diagnosis -- 8.4 Neuroendocrine Dysfunctions of FHA -- 8.5 Stress as Defensive System -- References -- 9: Amenorrhoea and Anorexia Nervosa in Adolescent Girls -- 9.1 Features of Amenorrhoea in AN -- 9.2 Amenorrhoea a Criteria of AN ? -- 9.3 Therapeutics Implications -- References
  • 10: The Long-Term Cardiovascular Risks Associated with Amenorrhea -- References -- 11: Delayed Puberty: Impact on Female Fertility -- 11.1 Introductory Remarks -- 11.2 Normal Puberty -- 11.2.1 Clinical Aspects -- 11.2.2 Endocrinological Aspects of Normal Puberty -- 11.2.2.1 Adrenarche -- 11.2.2.2 Regulation of the Hypothalamo-Hypophyseal-{u00AD}Gonadal Axis -- 11.2.3 Pubertal Maturation of the Hypothalamo-Hypophyseal-{u00AD}Gonadal Axis (Fig. 11.5) -- 11.2.4 Acceleration of Puberty -- 11.3 Delayed Puberty -- 11.3.1 Definition -- 11.3.2 Incidence -- 11.3.3 When and How to Investigate? -- 11.3.3.1 Hormone Measurements -- Gonadotropins -- Oestradiol -- Inhibin B and Anti-Müllerian Hormone (AMH) -- Other Hormones to be Checked -- 11.3.3.2 Bone Age -- 11.3.3.3 Pelvic Abdominal Ultrasonography -- 11.3.3.4 Karyotype -- 11.3.3.5 Brain Magnetic Resonance Imaging (MRI) -- 11.4 Impact on Fertility of the Different Forms of Delayed Puberty -- 11.4.1 Constitutional Delay of Growth and Puberty -- 11.4.2 Other Forms of Hypogonadotropic Delay of Growth and Puberty -- 11.4.2.1 Hypothalamic Hypogonadotropic Hypogonadism (Primary Ovarian Insufficiency) -- Delay of Puberty in Organic Hypothalamic Hypogonadotropic Hypogonadism (HH) (Table 11.2a) -- Isolated GnRH Deficiency -- Delay of Puberty in Functional Hypogonadal Hypogonadism (Primary Ovarian Insufficiency) -- 11.4.2.2 Delay of Puberty in Hypophyseal Hypogonadotrophic Hypogonadism (Secondary Ovarian Insufficiency) -- 11.4.2.3 Impact on Fertility -- 11.4.2.4 Profertile Measures: Ovulation Induction in Hypogonadotropic Hypogonadism (Primary and Secondary Ovarian Insufficiency) -- 11.4.3 Delay of Puberty in Hypergonadotropic Hypogonadism (Table 11.8) -- 11.4.3.1 Congenital Forms -- Gonadal Dysgenesis: Phenotypic Female Variants -- Turner Syndrome -- Other Forms of Gonadal Dysgenesis -- Noonan Syndrome
  • Androgen Insensitivity Syndrome, Testicular Feminization ("Hairless Women") -- Mutations in LH or FSH Receptor -- Galactosemia -- 11.4.3.2 Acquired Forms -- Delayed Puberty and Reduced Fertility After Cancer Treatment -- Effect of Chemotherapy and Radiotherapy -- Chemotherapy -- Effect of Radiotherapy -- Estimation of the Damage Induced by Chemotherapy and Radiotherapy by Biological Markers and By Sonography -- Fertility Preservation in Young Girls and in Adolescents -- Oncological Indications -- Non-Oncological Indications -- Ethical Considerations -- Acquired Delayed Puberty and Reduced Fertility Due to Other Causes -- Ovarian Torsion and Gonadectomy -- Autoimmune Diseases -- Endocrine Disruptors -- References -- 12: Premature Ovarian Failure in Adolescence and Young Adults: From Diagnosis to Therapy and Follow-up for Fertility Preservation -- References -- 13: Emergency Contraception -- 13.1 Introduction -- 13.2 Efficacy Assumptions -- 13.3 Effectiveness, Acceptability and Availability -- 13.4 Mechanism of Action and Effect on Pregnancy -- 13.5 Factors Predictive of Failure of EC -- 13.6 Can EC Prevent Abortion? -- 13.7 Establishing Effective Contraception After EC -- 13.8 Contraception After Ulipristal Acetate for Contraception -- 13.9 A More Effective Oral EC -- References -- 14: Adolescent Pregnancy and Contraception -- 14.1 Adolescent Pregnancy [1-3] -- 14.1.1 Complications During Pregnancy -- 14.1.2 Adolescent Pregnancy-Effect on Newborn -- 14.1.3 Social Aspects -- 14.2 Adolescent Contraception -- 14.3 Barriers for Contraception Use -- 14.4 Emergency Contraception (EC) -- 14.4.1 Mechanism of Action of EC -- 14.4.2 Available EC Options -- 14.4.3 Contraindications -- 14.4.4 Efficacy of EC in Overweight and Obese Adolescents -- 14.4.5 Resuming or Initiating Hormonal Contraception -- 14.4.6 Repeated Emergency Contraception
  • 14.4.7 Adolescents Who Are Using EC as a Primary Method
http://library.link/vocab/cover_art
https://contentcafe2.btol.com/ContentCafe/Jacket.aspx?Return=1&Type=S&Value=9783319414331&userID=ebsco-test&password=ebsco-test
Dimensions
unknown
http://library.link/vocab/discovery_link
{'f': 'http://opac.lib.rpi.edu/record=b4387512'}
Extent
1 online resource (239 pages)
Form of item
online
Isbn
9783319414331
Media category
computer
Media MARC source
rdamedia
Media type code
c
Sound
unknown sound
Specific material designation
remote

Library Locations

    • Folsom LibraryBorrow it
      110 8th St, Troy, NY, 12180, US
      42.729766 -73.682577
Processing Feedback ...